What is patent exhaustion (the first-sale doctrine)?

Patent exhaustion (also called the first-sale doctrine) holds that the initial authorized sale of a patented item terminates all patent rights in that item, allowing the buyer and all downstream purchasers to use, resell, or repair the item without liability for patent infringement.

The doctrine operates through the text of 35 U.S.C. § 271(a), which makes infringement dependent on acting "without authority" from the patentee. Once the patentee authorizes a sale, subsequent use of that particular item is "with authority," so § 271(a) cannot reach it.

Why the doctrine exists

The exhaustion doctrine reflects the common-law principle against restraints on alienation: patent rights yield once the patentee has received its reward through the authorized sale. Patent law grants a limited monopoly to encourage invention and disclosure; it does not entitle the patentee to extract further value from every downstream transaction involving the same physical item.

Post-sale restrictions cannot override exhaustion

A recurring practical question is whether a patentee can preserve patent-enforcement rights by attaching conditions to a sale (for example, "single use only," "no resale," or "not for export"). After the Supreme Court's decision in Impression Products, Inc. v. Lexmark International, Inc. (2017), the answer is no, as far as patent law is concerned.

The Court held that a patentee's decision to sell a product exhausts all of its patent rights in that item, regardless of any restrictions the patentee purports to impose on post-sale use or resale. After the authorized sale, post-sale restrictions cannot be enforced through patent infringement claims; only contract remedies between the immediate parties remain available.

The distinction is significant for practitioners. A post-sale restriction that a direct buyer contractually accepted remains enforceable under contract law against that buyer, even though the same restriction cannot be enforced against downstream parties through a patent infringement claim. If the patentee needs broad downstream control over how its product is used, the correct structure is a license (which transfers only limited rights, not title) rather than an outright sale.

Authorized foreign sales exhaust U.S. rights

Before 2017, the Federal Circuit had held that authorized foreign sales did not exhaust U.S. patent rights, leaving U.S. patentees free to re-assert their patents against re-imports of goods they had already sold abroad. Impression Products rejected this approach: the Supreme Court held that an authorized sale outside the United States exhausts all U.S. patent rights in that item, just as an authorized domestic sale does.

This ruling directly affects importation strategy. A patentee who authorizes the sale of goods in a foreign market cannot then use U.S. patent infringement claims to block re-importation of those same items by gray-market importers. Other tools, such as trademark, customs law, or contract, may still be available depending on the circumstances, but the U.S. patent is exhausted once the authorized foreign sale is made.

Method patents: the Quanta rule

Before 2008, there was uncertainty about whether method (process) patent claims could be exhausted through product sales, since methods are practiced rather than sold as tangible articles. The Supreme Court resolved this in Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008), holding that method patent claims are not categorically immune from exhaustion and can be exhausted through authorized product sales.

The applicable test is the "substantially embodies" standard: exhaustion of method claims through a product sale requires that the product contain all inventive aspects of the patented method and have no reasonable noninfringing use.

In Quanta, Intel held a license from LG Electronics permitting it to manufacture and sell microprocessors and chipsets. LG argued its method patents survived because Quanta (the buyer) had never been licensed. The Court disagreed: Intel's authorized sales exhausted LG's method claims because the Intel components embodied all inventive aspects of the patented methods and required only standard combining steps. When a licensee makes a sale within the scope of its patent license, that sale is authorized for exhaustion purposes and protects downstream purchasers from patent infringement claims, even if the patentee has separately imposed restrictions on those downstream purchasers by agreement.

The practical consequence: do not assume that drafting claims as method claims insulates a patent from exhaustion. If a sold product substantially embodies the method, the method claim exhausts along with any product claim.

What does and does not trigger exhaustion

Authorized sales trigger exhaustion. This includes direct sales by the patentee and sales by a licensee acting within the scope of its license. An unauthorized sale, meaning one made without the patentee's express or implied permission, does not trigger exhaustion; patent rights survive and can be enforced against downstream users of goods from that sale.

A sale outside the scope of a license (for example, one that violates a geographic restriction or field-of-use limitation in the license) is not an authorized sale for exhaustion purposes, because the patentee never consented to that particular transaction.

Exhaustion protects use and resale, not replication. The Supreme Court held in Bowman v. Monsanto Co., 569 U.S. 278 (2013), that patent exhaustion does not allow a buyer to make additional copies of the patented invention; exhaustion protects the right to use and resell the specific item purchased, not the right to replicate the invention. The farmer in Bowman could use the patented seeds he purchased; he could not grow and harvest additional generations of patented seeds without authorization, because doing so constituted making new patented articles.

Exhaustion scenarios at a glance

Practical notes for practitioners

• Check the scope of any license before asserting infringement against a downstream buyer. If your client's patent was licensed and the licensee's sale was within that license scope, the downstream buyer has exhaustion as a complete defense to a patent infringement claim.
• Post-sale restrictions belong in contracts, not patent claim strategies. After Impression Products, patent law cannot reach downstream behavior. Draft supply and distribution agreements carefully if downstream use or resale matters; the only tools left for controlling downstream conduct are contract and, where applicable, trademark or trade dress.
• Gray-market imports require careful analysis. If the U.S. patentee authorized the foreign sale, the U.S. patent cannot stop importation of those items. Investigate whether the foreign sale was truly authorized, whether any trademark rights offer a separate remedy, and whether customs recordation under trademark applies.
• Method claims do not avoid exhaustion. Analyze whether the accused downstream activity involves a product that substantially embodies a method claim. If so, apply the Quanta test: does the product contain all inventive aspects of the method, and does it have a reasonable noninfringing use? If both conditions are met, the method claim is exhausted.
• Distinguish a sale from a license when structuring transactions. Exhaustion attaches to a sale (a transfer of title). A true license, which transfers only the right to use without transferring ownership of the article, may not trigger exhaustion. The label a party puts on a transaction is not dispositive; courts look at the economic substance of the arrangement.